Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model

Molecular Immunology

Volumn 59, Issue 1, 2014, Pages 91-99

  Makam, Shivakiran S ^a   Kingston, Joseph J ^a   Harischandra, Murali S ^a   Batra, Harsh V ^a  

^a DEFENCE FOOD RESEARCH LABORATORY   (India)

Author keywords

Bacillus anthracis; Chimeric protein; Extractable antigen 1; Immune response; Protection; Protective antigen

Indexed keywords

ANTIGEN; CHIMERIC PROTEIN; EXTRACTABLE ANTIGEN 1; IMMUNOGLOBULIN G1; PROTECTIVE ANTIGEN 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; CELLULAR IMMUNITY; CONTROLLED STUDY; EDEMA; FEMALE; HELPER CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OPSONIZATION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; T LYMPHOCYTE;

BACILLUS ANTHRACIS; CHIMERIC PROTEIN; EXTRACTABLE ANTIGEN 1; IMMUNE RESPONSE; PROTECTION; PROTECTIVE ANTIGEN;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BINDING SITES; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; EDEMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE SERA; IMMUNIZATION; IMMUNOGLOBULIN G; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SPLEEN; SURVIVAL ANALYSIS;

EID: 84893595208     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.01.012     Document Type: Article

References (37)

1. Aulinger B.A., Roehrl M.H., Mekalanos J.J., Collier R.J., Wang J.Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect. Immun. 2005, 73(6):2408-3414.
2. Baillie L., Hebdon R., Flick-Smith H., Williamson D. Characterization of the immune response to the UK human anthrax vaccine. FEMS Immunol. Med. Microbiol. 2003, 36:83-86.
3. Brahmbhatt T.N., Darnell S.C., Caarvalho H.M., Sanz P., Kang T.J., Bull R.L., Rasmussen S.B., Cross A.S., O'Brien A.D. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect. Immun. 2007, 75(11):5240-5247.
4. Brossier F., Sirard J.C., Guidi-Rontani C., Duflot E., Mock M. Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect. Immun. 1999, 67(2):964-967.
5. Chabot D.J., Scorpio A., Tobery S.A., Little S.F., Norris S.L., Friedlander A.M. Anthrax capsule vaccine protects against experimental infection. Vaccine 2004, 23:43-47.
6. Chichester J.A., Musiychuk K., Rosa P., Horsey A., Stevenson N., Ugulava N., Rabindran S., Palmer G.A., Mett V., Yusibov V. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007, 25:3111-3114.
7. Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., others Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect. Immun. 2000, 68(8):4549-4558.
8. Cote C.K., Rossi C.A., Kang A.S., Morrow P.R., Leed J.S., Welkos S.L. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb. Pathog. 2005, 38:209-225.
9. Cote C.K., Bozue J., Moody K.L., DiMezzo T.L., Chapman C.E., Welkos S.L. Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization. Microbiology 2008, 154:619-632.
10. Cote C.K., Welkos S.L., Bozue J. Key aspects of the molecular and cellular basis of inhalational anthrax. Microbes Infect. 2011, 13:1146-1155.
11. Cote C.K., Kaatz L., Reinhardt J., Bozue J., Tobery S.A., Bassett A.D., Sanz P., Darnell S.C., Alem F., O'Brien A.D., Welkos S.L. Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia. J. Med. Microbiol. 2012, 61:1380-1392.
12. Enkhtuya J., Kawamoto K., Kobayashi Y., Uchida I., Rana N., Makino S. Significant passive protection effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids. Microbiology 2006, 152:3103-3110.
13. Farchaus J.W., Ribot W.J., Jendrek S., Little S.F. Fermentation, purification, characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl. Environ. Microbiol. 1998, 64(3):982-991.
14. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., Titball R.W., Williamson E.W. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 2002, 70(4):1653-1656.
15. Fouet A. The surface of Bacillus anthracis. Mol. Aspects Med. 2009, 30:374-385.
16. Gorantala J., Grover S., Goel D., Rahi A., Magani S.K.J., Chandra S., Bhatnagar R. A plant based protective antigen [PA (dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax. Vaccine 2011, 29:4521-4533.
17. Kaur M., Chug H., Singh H., Chandra S., Mishra M., Sharma M., Bhatnagar R. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Mol. Immunol. 2009, 46:2107-2115.
18. Kelly-Cirino C.D., Mantis N.J. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect. Immun. 2009, 77(11):4859-4867.
19. Koya V., Moayeri M., Leppla S.H., Daniell H. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect. Immun. 2005, 73(12):8266-8274.
20. Makam S.S., Kingston J.J., Majumder S., Urs R.M., Tuteja U., Sripathi M.H., Batra H.V. Immunocapture PCR for rapid and sensitive detection of pathogenic Bacillus anthracis. World J. Microbiol. Biotechnol. 2013, 29(12):2379-2388.
21. Mesnage S., Fontaine T., Mignot T., Delepierre M., Mock M., Fouet A. Bacterial SLH domain proteins are non-covalently anchored to the cell surface via a conserved mechanism involving wall polysaccharide pyruvylation. EMBO J. 2000, 19(17):4473-4484.
22. McConnell M.J., Hanna P.C., Imperiale M.J. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect. Immun. 2006, 74(2):1009-1015.
23. Mock M., Fouet A. Anthrax. Annu. Rev. Microbiol. 2001, 55:647-671.
24. Park Y.S., Lee J.H., Hung C., Wu T.C., Kim T.W. Enhancement of antibody to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect. Immun. 2008, 76(5):1952-1959.
25. Rhie G., Roehrl M.H., Mourez M., Collier J.R., Mekalanos J.J., Wang J.Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10925-10930.
26. Schneerson R., Kubler-Kielb J., Liu T.Y., Dai Z.D., Leppla S.H., Yergey A., Backlund P., Shiloach J., Majadly F., Robbins J.B. Poly (gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8945-8950.
27. Sloat B.R., Shaker D.S., Le U.M., Cui Z. Nasal immunization with the mixture of PA63 LF, and aPGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol. Med. Microbiol. 2008, 52:169-179.
28. Stepanov A.V., Marinin L.I., Pomerantsev A.P., Staritsin N.A. Development of novel vaccines against anthrax in man. J Biotechnol. 1996, 44:155-160.
29. Uchida M., Harada T., Enkhtuya J., Kusumoto A., Kobayashi Y., others Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice. Biochem. Biophys. Res. Commun. 2012, 421:323-328.
30. Varughese M., Teixeira A.V., Liu S., Leppla S.H. Identification of a receptor binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 1999, 67(4):1860-1865.
31. Vergis J.M., Cote C.K., Bozue J., Alem F., Ventura C.L., Susan L., Welkos S.L., O'Briena A.D. Immunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis Ames. Clin. Vaccine Immunol. 2013, 20(1):56-65.
32. Wang T.T., Fellows P.F., Leighton T.J., Lucas A.H. Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol. Med. Microbiol. 2004, 40:231-237.
33. Wang J.Y., Roehrl M.H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med. Immunol. 2005, 4:4.
34. Wang Y., Jiang N., Zhan D., Tao H., Yuan S., Wang P., Wang L., Zhang Z., Liu C. Surface display of the 20-kDa N-terminal fragment of anthrax protective antigen based on attenuated recombinant Bacillus anthracis. World J. Microbiol. Biotechnol. 2011, 27:2575-2581.
35. Welkos S., Friedlander A., Weeks S., Little S., Mendelson I. In vitro characterization of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J. Med. Microbiol. 2002, 51:821-831.
36. Welkos S., Little S., Friedlander A., Fritz D., Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001, 147:1677-1685.
37. Williams D.D., Turnbough C.L. Surface layer protein EA1 is not a component of Bacillus anthracis spores but is a persistent contaminant in spore preparations. J. Bacteriol. 2004, 186(2):566-569.